Incomplete and Unreported: Failure to Report Results of Incomplete Studies Results in Publication Bias

AJOB Primary Research

Volumn 3, Issue 4, 2012, Pages 1-18

  Shamliyan, Tatyana ^a   Kane, Robert L ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

clinical trials as topic; National Institutes of Health (U.S.); National Library of Medicine (U.S.); publishing; registries; research peer review; research support as topic

Indexed keywords

EID: 84868707242     PISSN: 21507716     EISSN: 21507724     Source Type: Journal    
DOI: 10.1080/21507716.2012.714835     Document Type: Article

References (52)

1. Assessment of the Safety and Efficacy of a New Treatment Strategy with Percutaneous Coronary Intervention (ASSENT-4 PCI) Investigators. 2006. Primary versus tenecteplase-facilitated percutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction (ASSENT-4 PCI): Randomised trial. Lancet, 367(9510): 569-578.
2. Chan, A. W., Laupacis, A. and Moher, D. 2010. Registering results from clinical trials. Journal of the American Medical Association, 303(21): 2138-2139. author reply 2139
3. Chou, R., Aronson, N., Atkins, D., Ismaila, A. S., Santaguida, P., Smith, D. H., Whitlock, E., Wilt, T. J. and Moher, D. 2010. AHRQ series paper 4: Assessing harms when comparing medical interventions: AHRQ and the effective health-care program. Journal of Clinical Epidemiology, 63(5): 502-512.
4. Clancy, C. and Brookings Institution. 2010. Using comparative effectiveness research to improve the health of priority populations, Washington, DC: Brookings Institution.
5. Clancy, C. M., Slutsky, J. R. and Patton, L. T. 2004. Evidence-based health care 2004: AHRQ moves research to translation and implementation. Health Services Research, 39(5): xv-xxiii.
6. de Wit, M., Gennings, C., Jenvey, W. I. and Epstein, S. K. 2008. Randomized trial comparing daily interruption of sedation and nursing-implemented sedation algorithm in medical intensive care unit patients. Critical Care, 12(3): R70
7. Department of Health and Human Services. 1990a. Code of Federal Regulations, 21 CFR (Chapter 1-Food and Drug Administration): Part 50 Protection of Human Subjects, Washington, DC: National Archives and Records Administration.
8. Department of Health and Human Services. 1990b. Code of Federal Regulations, 21 CFR (Chapter I-Food and Drug Administration): Part 312: Investigational New Drug Application, and Part 812: Investigational Device Exemptions, Washington, DC: National Archives and Records Administration.
9. Department of Health and Human Services, Office of the Secretary, and Food and Drug Administration. 2011. Advance notice of proposed rulemaking (ANPRM), human subjects research protections: Enhancing protections for research subjects and reducing burden, delay, and ambiguity for investigators, Washington, DC: National Archives and Records Administration. 45 CFR Parts 46, 160, and 164
10. Dickersin, K. 1990. The existence of publication bias and risk factors for its occurrence. Journal of the American Medical Association, 263(10): 1385-1359.
11. Dickersin, K. 1997. How important is publication bias? A synthesis of available data. AIDS Educcation and Prevention, 9(1 SUPPL.): 15-21.
12. Dwan, K., Altman, D. G., Arnaiz, J. A., Bloom, J., Chan, A. W., Cronin, E., Decullier, E., Easterbrook, P. J., Von Elm, E., Gamble, C., Ghersi, D., Ioannidis, J. P., Simes, J. and Williamson, P. R. 2008. Systematic review of the empirical evidence of study publication bias and outcome reporting bias. PLoS One, 3(8): e3081
13. Egger, M. and Smith, G. D. 1998. Bias in location and selection of studies. British Medical Journal, 316(7124): 61-66.
14. English, R. A., Lebovitz, Y., Giffin, R. B., Institute of Medicine, Forum on Drug Discovery Development and Translation and National Academies Press. 2010. Transforming clinical research in the United States: Challenges and opportunities: Workshop summary, Washington, DC: National Academies Press.
15. Ferring Pharmaceuticals. 2009. Extension Study investigating the long-term safety and tolerability of repeat doses of FE200486 in prostate cancer patients. Available at: http://clinicaltrials.gov/ct2/show/study/NCT00215657?term=NCT00215657&rank=1 (accessed Feburary 2009)
16. Food and Drug Administration. 1997. Food and Drug Administration modernization act (FDAMA) of 1997.
17. Food and Drug Administration. 2010a. Amendments act of 2007. Public Law No. 110-85, 121 Stat 823, 904, Title VIII (September 27, 2007), 42 USC 282(j) (Supp. 2009)
18. Food and Drug Administration. 2010b. Draft proposals for public comment regarding disclosure policies of the U.S. Food and Drug Administration. FDA transparency initiative 2010 (August). Available at: http://www.fda.gov/downloads/AboutFDA/WhatWeDo/FDATransparencyTaskForce/TransparencyReport/GlossaryofAcronymsandAbbreviations/UCM212110.pdf (acessed December 15, 2011)
19. Food and Drug Administration Amendments Act of 2007. 2007. Sec. 801. Expanded clinical trial registry data bank. Public Law 110-85. September 27. Available at: http://www.fda.gov/RegulatoryInformation/Legislation/FederalFoodDrugandCosmeticActFDCAct/SignificantAmendmentstotheFDCAct/FoodandDrugAdministrationAmendmentsActof2007/FullTextofFDAAALaw/default.htm (accessed December 13, 2011)
20. Godlee, F. and Loder, E. 2010. Missing clinical trial data: Setting the record straight. British Medical Journal, 341: c5641
21. Health and Human Services. 2009. Code of Federal Regulations Title 45 Public Welfare Department of Health and Human Services Part 46.
22. Hopewell, S., Loudon, K., Clarke, M. J., Oxman, A. D. and Dickersin, K. 2009. Publication bias in clinical trials due to statistical significance or direction of trial results. Cochrane Database of Systematic Reviews, 1: MR000006
23. Institute of Medicine. 2011. Finding what works in health care: Standards for systematic reviews, Washington, DC: National Academies Press.
24. Institute of Medicine Committee on Comparative Effectiveness Research Prioritization and Institute of Medicine. 2009. Initial national priorities for comparative effectiveness research, Washington, DC: Institute of Medicine of the National Academies.
25. Kawald, A., Burmester, G. R., Huscher, D., Sunderkotter, C. and Riemekasten, G. 2008. Low versus high-dose iloprost therapy over 21 days in patients with secondary Raynaud's phenomenon and systemic sclerosis: a randomized, open, single-center study. Journal of Rheumatology, 35(9): 1830-1837.
26. Kuller, L. H., Kriska, A. M., Kinzel, L. S., Simkin-Silverman, L. R., Sutton-Tyrrell, K., Johnson, B. D. and Conroy, M. B. 2007. The clinical trial of Women On the Move through Activity and Nutrition (WOMAN) study. Contemporary Clinical Trials, 28(4): 370-381.
27. Law, M. R., Kawasumi, Y. and Morgan, S. G. 2011. Despite law, fewer than one in eight completed studies of drugs and biologics are reported on time on ClinicalTrials. Health Affairs (Millwood) gov, 30(12): 2338-2345.
28. Lipshultz, S. E., Rifai, N.Dalton, V. M. 2004. The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. New England Journal of Medicine, 351(2): 145-153.
29. Mancini, J. and Reynier, C. J. 2010. Registering results from clinical trials. Journal of the American Medical Association, 303(21): 2139 author reply 2139
30. Mathieu, S., Boutron, I., Moher, D., Altman, D. G. and Ravaud, P. 2009. Comparison of registered and published primary outcomes in randomized controlled trials. Journal of the American Medical Association, 302(9): 977-984.
31. McGauran, N., Wieseler, B., Kreis, J., Schuler, Y. B., Kolsch, H. and Kaiser, T. 2010. Reporting bias in medical research-A narrative review. Trials, 11: 37
32. Miller, J. D. 2010. Registering clinical trial results: The next step. Journal of the American Medical Association, 303(8): 773-774.
33. Moher, D. 2007. Reporting research results: A moral obligation for all researchers. Canadian Journal of Anaesthia, 54(5): 331-335.
34. Office of Research Integrity (ORI). 2009. Responsible conduct of research (RCR). Available at: http://ori.dhhs.gov/education (accessed June 16 2012)
35. One Hundred Fifth Congress of the United States of America. 1997. Food and Drug Administration Modernization Act of 1997. Public Law 105-115, Sec. 113, Information Program on Clinical trials for Serious or Life-Threatening Diseases. Available at: http://www.gpo.gov/fdsys/pkg/PLAW-105publ115/html/PLAW-105publ115.htm (accessed September 2012)
36. Psaty, B. M. and Rennie, D. 2003. Stopping medical research to save money: A broken pact with researchers and patients. Journal of the American Medical Association, 289(16): 2128-2131.
37. Reyes, M. M., Panza, K. E., Martin, A. and Bloch, M. H. 2011. Time-lag bias in trials of pediatric antidepressants: A systematic review and meta-analysis. Journal of the American Academy of Child and Adolescent Psychiatry, 50(1): 63-72.
38. SAS Institute, Inc. 2008. SAS version 9.1.3. Six CD-ROMs, Chicago, IL: SAS Institute, Inc.
39. Sasako, M., Sano, T.Yamamoto, S. 2006. Left thoracoabdominal approach versus abdominal-transhiatal approach for gastric cancer of the cardia or subcardia: A randomised controlled trial. Lancet Oncology, 7(8): 644-651.
40. Shamliyan, T. 2010. Reporting of results of interventional studies by the information service of the National Institutes of Health. Clinical Pharmacology: Advances and Applications, 2010(2): 169-176.
41. Sica, D. A. 2001. Pharmacotherapy in congestive heart failure. Prematurely terminated clinical trials and their application to cardiovascular medicine. Congestive Heart Failure, 7(5): 265-271.
42. Slutsky, J. R. and Clancy, C. M. 2005. The Agency for Healthcare Research and Quality's Effective Health Care Program: Creating a dynamic system for discovering and reporting what works in health care. American Journal of Medical Quality, 20(6): 358-360.
43. Sterne, J. A., Gavaghan, D. and Egger, M. 2000. Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature. Journal of Clinical Epidemiology, 53(11): 1119-1129.
44. Tse, T., Williams, R. J. and Zarin, D. A. 2009. Update on registration of clinical trials in ClinicalTrials.gov. Chest, 136(1): 304-305.
45. Turner, E. H., Matthews, A. M., Linardatos, E., Tell, R. A. and Rosenthal, R. 2008. Selective publication of antidepressant trials and its influence on apparent efficacy. New England Journal of Medicine, 358(3): 252-260.
46. Vichinsky, E. P., Neumayr, L. D.Gold, J. I. 2010. Neuropsychological dysfunction and neuroimaging abnormalities in neurologically intact adults with sickle cell anemia. Journal of the American Medical Association, 303(18): 1823-1831.
47. Wieseler, B., McGauran, N. and Kaiser, T. 2010. Finding studies on reboxetine: A tale of hide and seek. British Medical Journal, 341: c4942
48. World Association of Medical Editors (WAME) Editorial Policy Committee. 2005. The registration of clinical trials. Available at: http://www.wame.org/resources/policies#trialreg (accessed September 2012)
49. World Health Organization. 2010. International clinical trials registry platform. Available at: http://www.who.int/ictrp/en/ (accessed September 2012)
50. World Medical Association. 2000. World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects. Journal of the American Medical Association, 284(23): 3043-3045.
51. Wyeth. 2010. A randomized, open-label, comparative evaluation of conversion from calcineurin inhibitor treatment to sirolimus treatment versus continued calcineurin inhibitor treatment in liver allograft recipients undergoing maintenance therapy. Available at: http://clinicaltrials.gov/ct2/show/NCT00086346?term=NCT000 86346&rank=1 (accessed February 2010)
52. Zarin, D. A., Tse, T., Williams, R. J., Califf, R. M. and Ide, N. C. 2011. The ClinicalTrials.gov results database-Update and key issues. New England Journal of Medicine, 364(9): 852-860.